S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
The Collapse of 2022 Has Begun (Ad)pixel
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"The Bull Market Is Officially OVER"  (Ad)pixel
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
"The Bull Market Is Officially OVER"  (Ad)pixel
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
The Collapse of 2022 Has Begun (Ad)pixel
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"The Bull Market Is Officially OVER"  (Ad)pixel
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
"The Bull Market Is Officially OVER"  (Ad)pixel
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
The Collapse of 2022 Has Begun (Ad)pixel
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"The Bull Market Is Officially OVER"  (Ad)pixel
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
"The Bull Market Is Officially OVER"  (Ad)pixel
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
The Collapse of 2022 Has Begun (Ad)pixel
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
"The Bull Market Is Officially OVER"  (Ad)pixel
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
"The Bull Market Is Officially OVER"  (Ad)pixel
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NASDAQ:FENC

Fennec Pharmaceuticals - FENC Stock Forecast, Price & News

$9.76
+0.01 (+0.10%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.63
$10.06
50-Day Range
$7.18
$9.76
52-Week Range
$3.82
$10.06
Volume
177,608 shs
Average Volume
74,102 shs
Market Capitalization
$256.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.83

Fennec Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
52.0% Upside
$14.83 Price Target
Short Interest
Healthy
2.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.03mentions of Fennec Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.85) to ($0.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

721st out of 1,043 stocks

Biological Products, Except Diagnostic Industry

117th out of 172 stocks

FENC stock logo

About Fennec Pharmaceuticals (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Stock News Headlines

Expert Ratings for Fennec Pharmaceuticals
Where Fennec Pharmaceuticals Stands With Analysts
4 Analysts Have This to Say About Fennec Pharmaceuticals
What 4 Analyst Ratings Have To Say About Fennec Pharmaceuticals
U.S. FDA approves Fennec's hearing loss therapy
Will Fennec's Pedmark Cross FDA Finish Line This Time?
Fennec Resubmits Pedmark NDA To FDA
See More Headlines
Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FENC Company Calendar

Last Earnings
11/11/2022
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FENC
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.83
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+52.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-17,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$170,000.00
Book Value
$0.11 per share

Miscellaneous

Free Float
23,777,000
Market Cap
$256.08 million
Optionable
Optionable
Beta
N/A

Key Executives

  • Mr. Rostislav Raykov (Age 42)
    Pres, CEO & Director
  • Mr. Robert C. Andrade (Age 43)
    Chief Financial Officer
  • Mr. Mark Gowland
    Controller
  • Mr. Lei Fang
    Pres of Pharstat Inc
  • Ms. Anne McKay (Age 64)
    Regulatory Consultant













FENC Stock - Frequently Asked Questions

Should I buy or sell Fennec Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FENC shares.
View FENC analyst ratings
or view top-rated stocks.

What is Fennec Pharmaceuticals' stock price forecast for 2023?

6 brokerages have issued 1-year price targets for Fennec Pharmaceuticals' stock. Their FENC share price forecasts range from $11.00 to $19.00. On average, they anticipate the company's stock price to reach $14.83 in the next year. This suggests a possible upside of 52.0% from the stock's current price.
View analysts price targets for FENC
or view top-rated stocks among Wall Street analysts.

How have FENC shares performed in 2022?

Fennec Pharmaceuticals' stock was trading at $4.40 on January 1st, 2022. Since then, FENC shares have increased by 121.8% and is now trading at $9.76.
View the best growth stocks for 2022 here
.

When is Fennec Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our FENC earnings forecast
.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) issued its earnings results on Friday, November, 11th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.14.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include 683 Capital Management LLC (1.47%), Tamarack Advisers LP (0.67%), Group One Trading L.P. (0.00%), BlackRock Inc. (0.19%), Hartford Financial Management Inc. (0.15%) and Jane Street Group LLC (0.06%).
View institutional ownership trends
.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $9.76.

How much money does Fennec Pharmaceuticals make?

Fennec Pharmaceuticals (NASDAQ:FENC) has a market capitalization of $256.08 million and generates $170,000.00 in revenue each year. The company earns $-17,350,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The official website for the company is www.fennecpharma.com. The company can be reached via phone at 919-636-4530 or via fax at 919-890-0490.

This page (NASDAQ:FENC) was last updated on 12/1/2022 by MarketBeat.com Staff